ADC Therapeutics SA
NYSE:ADCT
Relative Value
The Relative Value of one ADCT stock under the Base Case scenario is 5.51 USD. Compared to the current market price of 4.49 USD, ADC Therapeutics SA is Undervalued by 19%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ADCT Competitors Multiples
ADC Therapeutics SA Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CH |
ADC Therapeutics SA
NYSE:ADCT
|
370.6m USD | 5.3 | -1.5 | -3.2 | -3.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
321.6B USD | 5.9 | 66.7 | 14.3 | 21.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
152.2B USD | 5.4 | 22.7 | 16.7 | 25 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 10.9 | 29.8 | 23.9 | 25.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.3B USD | 8 | 26.6 | 18 | 19.8 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
91.3B USD | 3.4 | 16.1 | 9.6 | 12.8 | ||
AU |
CSL Ltd
ASX:CSL
|
139.1B AUD | 6.4 | 36.7 | 22.1 | 27.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
40.7B USD | 5.9 | -8.6 | -9 | -7.7 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.2B USD | 3.2 | 26.9 | 14.5 | 18 | ||
KR |
Celltrion Inc
KRX:068270
|
41.5T KRW | 18 | 68.8 | 43.2 | 56.7 |